Indaptus Therapeutics
INDP
5 hedge funds and large institutions have $9.46M invested in Indaptus Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
12% more capital invested
Capital invested by funds: $8.47M → $9.46M (+$996K)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$2.47M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$11.1K |
| 3 |
Renaissance Technologies
New York
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$791K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $4.14M | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $2.65M | – | – | – |
|
|
MIFH
3
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
| $2.54M | +$2.47M | +222 | New |
|
|
4
Renaissance Technologies
New York
| $66K | +$11.1K | +1 | +20% |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $65K | +$11.1K | +1 | +20% |
|
|
NC
6
Nexthera Capital
New York
| – | -$791K | -62 | Closed |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$5K | – | – |
|
INDP Hedge Fund Activity: Q1 2017 in Review
5 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2017, worth a combined $9.46M — up 12% from $8.47M a quarter earlier.
Fund positioning in INDP was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Migdal Insurance & Financial Holdings, opening a new position worth an estimated $2.47M. The largest seller was Nexthera Capital, exiting entirely with an estimated $791K sold.
- 5 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $9.46M of Indaptus Therapeutics stock for Q1 2017, up 12% quarter-over-quarter.
- 1 fund opened new Indaptus Therapeutics positions in Q1 2017 and 1 closed out, a net change of 0 holders.
- The largest Indaptus Therapeutics buyer in Q1 2017 was Migdal Insurance & Financial Holdings, an estimated $2.47M added.
- The largest Indaptus Therapeutics seller in Q1 2017 was Nexthera Capital, an estimated $791K sold.
Based on aggregated 13F filings for Q1 2017.